Form 4: Fortress Biotech Increases Stake in Checkpoint Therapeutics Through Equity Fee Grants

Fortress Biotech, a significant shareholder in Checkpoint Therapeutics, acquired additional shares through equity fee grants related to financing activities and an annual equity fee.

Summary

• Fortress Biotech, Inc. increased its holdings in Checkpoint Therapeutics, Inc. through the acquisition of common stock.
• On December 31, 2024, Fortress Biotech acquired 81,407 shares as an equity fee related to Checkpoint Therapeutics' financing activities.
• On January 1, 2025, Fortress Biotech acquired 2,386,808 shares as part of the annual equity fee grant, representing 2.5% of Checkpoint's fully diluted outstanding capitalization.
• Following these transactions, Fortress Biotech's total holdings in Checkpoint Therapeutics increased to 6,203,749 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports transactions related to pre-existing agreements. The increased stake could be seen as a positive, but it also involves dilution for other shareholders.

Positives

• Fortress Biotech's increased stake could signal confidence in Checkpoint Therapeutics' future prospects.
• The equity fee structure aligns Fortress Biotech's interests with Checkpoint Therapeutics' success in securing financing.

Risks

• The equity fee grants dilute existing shareholders' ownership in Checkpoint Therapeutics.
• The value of the shares acquired by Fortress Biotech is subject to the market performance of Checkpoint Therapeutics.

Industry Context

Equity fee arrangements are sometimes used in the biotech industry to compensate strategic investors or partners who provide financing or other valuable services. This arrangement suggests a close relationship between Fortress Biotech and Checkpoint Therapeutics.

Comparison to Industry Standards

• Equity financing and fee structures vary widely in the biotech industry depending on the stage of the company, the type of financing, and the specific agreements with investors.
• Comparing this arrangement to similar deals involving companies like Sorrento Therapeutics or NantKwest would require a detailed analysis of the specific terms and conditions.

Related Party Transactions

• The equity fee grants to Fortress Biotech are related-party transactions due to Fortress Biotech's significant ownership stake in Checkpoint Therapeutics.

Stakeholder Impact

• Shareholders of Checkpoint Therapeutics may experience dilution due to the issuance of new shares to Fortress Biotech.
• The arrangement benefits Fortress Biotech by increasing its ownership stake in Checkpoint Therapeutics.

Key Dates